环硅酸锆钠治疗血液透析伴高钾血症的临床研究进展

摘要/Abstract

摘要： 环硅酸锆钠是一种不被人体吸收，与K+结合进行阳离子交换的无机晶体化合物，主要作用部位在胃肠道内，高钾血症患者口服该药后1 h内即出现降钾活性。研究显示在血液透析伴高钾血症患者中，环硅酸锆钠均可安全、有效地降低患者血钾。但环硅酸锆钠作为治疗高钾血症的新型离子交换树脂，上市时间短，疗效和安全性尚未得到广泛验证。本文旨在对环硅酸锆钠在血液透析伴高钾血症患者中应用的研究进行归纳和总结，以期为临床用药提供参考。

关键词: 环硅酸锆钠, 高钾血症, 血液透析, 有效性, 不良反应

Abstract: Sodium zirconium cyclosilicate is an inorganic crystalline compound that can not be absorbed by the human body and is bound with K+ for cation exchange. Its main action site is in the gastrointestinal tract. Hypokalemia activity was observed within 1 h after oral administration in patients with hyperkalemia. Studies have shown that sodium zirconium cyclosilicate can safely and effectively reduce serum potassium in hemodialysis patients with hyperkalemia. However， SZC， as a new ion exchange resin for the treatment of hyperkalemia， has a short marketing time， and the extent to which it has been proven effective and safe has yet to be widely confirmed. This article aims to summarize the research on the application of sodium zirconium cyclosilicate in hemodialysis patients with hyperkalemia， in order to provide reference for followup research.

Key words: Sodium zirconium cyclosilicate, Hyperkalemia, Hemodialysis, Effectiveness, Adverse reactions

中图分类号:

R979.5

安兴宇, 李兴德, 宋沧桑, 毛盼盼, 张函舒, 王国徽. 环硅酸锆钠治疗血液透析伴高钾血症的临床研究进展[J]. 中国药物评价, 2023, 40(6): 512-516.

AN Xing-yu, LI Xing-de, SONG Cang-sang, MAO Pan-pan, ZHANG Han-shu, WANG Guo-hui. Clinical Research Progress of Sodium Zirconium Cyclosilicate in the Treatment of Hemodialysis with Hyperkalemia#br#[J]. CHINESE JOURNAL OF DRUG EVALUATION, 2023, 40(6): 512-516.

参考文献

[1] Fishbane S， Charytan DM， Chertow GM， et al. ConsensusBased Recommendations for the Management of Hyperkalemia in the Hemodialysis Setting[J]. J Ren Nutr， 2022，32(4)：e1e14.
[2] Yusuf AA， Hu Y， Singh B， et al. Serum Potassium Levels and Mortality in Hemodialysis Patients： A Retrospective Cohort Study[J]. Am J Nephrol， 2016，44(3)：179186.
[3] Agiro A， Duling I， Eudicone J， et al. The prevalence of predialysis hyperkalemia and associated characteristics among hemodialysis patients： The REUTILIZE study[J]. Hemodial Int， 2022，26(3)：397407.
[4] Kovesdy CP， Regidor DL， Mehrotra R， et al. Serum and dialysate potassium concentrations and survival in hemodialysis patients[J]. Clin J Am Soc Nephrol， 2007，2(5)：9991007.
[5] Bem D， Sugrue D， Wilding B， et al. The effect of hyperkalemia and long interdialytic interval on morbidity and mortality in patients receiving hemodialysis： a systematic review[J]. Ren Fail， 2021，43(1)：241254.
[6] Pirklbauer M. Hemodialysis treatment in patients with severe electrolyte disorders： Management of hyperkalemia and hyponatremia[J]. Hemodial Int， 2020，24(3)：282289.
[7] Shibata S， Uchida S. Hyperkalemia in patients undergoing hemodialysis： Its pathophysiology and management[J]. Ther Apher Dial， 2022，26(1)：314.
[8] Nguyen T， Ondrik D， Zhufyak O， et al. Hyperkalemia and potential pitfalls of sodium polystyrene sulfonate[J]. JAAPA， 2015，28(3)：4145.
[9] Noel JA， Bota SE， Petrcich W， et al. Risk of Hospitalization for Serious Adverse Gastrointestinal Events Associated With Sodium Polystyrene Sulfonate Use in Patients of Advanced Age[J]. JAMA Intern Med， 2019，179(8)：10251033.
[10] 中华医学会肾脏病学分会专家组. 中国慢性肾脏病患者血钾管理实践专家共识[J]. 中华肾脏病杂志， 2020，36(10)：781792.
[11] Clase CM， Carrero JJ， Ellison DH， et al. Potassium homeostasis and management of dyskalemia in kidney diseases： conclusions from a Kidney Disease： Improving Global Outcomes (KDIGO) Controversies Conference[J]. Kidney Int， 2020，97(1)：4261.
[12] Dong L， Xu W， Deng Y， et al. Efficacy and safety of potassium binders in the treatment of patients with chronic kidney disease and hyperkalemia[J]. Eur J Pharmacol， 2022，931：175174175182.
[13] Stavros F， Yang A， Leon A， et al. Characterization of structure and function of ZS9， a K+ selective ion trap[J]. PLoS One， 2014，9(12)：e114686e114697.
[14] Nassif ME， Kosiborod M. New frontiers for management of hyperkalaemia： the emergence of novel agents[J]. Eur Heart J Suppl， 2019，21(Suppl A)：A34A40.
[15] Oshima A， Imamura T， Narang N， et al. Management of hyperkalemia in chronic heart failure using sodium zirconium cyclosilicate[J]. Clin Cardiol， 2021，44(9)：12721275.
[16] Cases A， Gorriz JL. Sodium zirconium cyclosilicate： a new potassium binder for the treatment of hyperkalemia[J]. Drugs Today (Barc)， 2018，54(10)：601613.
[17] Rizk J， Quan D， Gabardi S， et al. Novel approaches to management of hyperkalaemia in kidney transplantation[J]. Curr Opin Nephrol Hypertens， 2021，30(1)：2737.
[18] Rossignol P. A new area for the management of hyperkalaemia with potassium binders： clinical use in nephrology[J]. Eur Heart J Suppl， 2019，21(Suppl A)：A48A54.
[19] Packham DK， Kosiborod M. Pharmacodynamics and pharmacokinetics of sodium zirconium cyclosilicate [ZS9] in the treatment of hyperkalemia[J]. Expert Opin Drug Metab Toxicol， 2016，12(5)：567573.
[20] Rosano G， Spoletini I， Agewall S. Pharmacology of new treatments for hyperkalaemia： patiromer and sodium zirconium cyclosilicate[J]. Eur Heart J Suppl， 2019，21(Suppl A)：A28A33.
[21] Shrestha DB， Budhathoki P， Sedhai YR， et al. Patiromer and Sodium Zirconium Cyclosilicate in Treatment of Hyperkalemia： A Systematic Review and MetaAnalysis[J]. Curr Ther Res Clin Exp， 2021，95：100635100643.
[22] Zhang Y， Xu R， Wang F， et al. Effects and Safety of a Novel Oral PotassiumLowering DrugSodium Zirconium Cyclosilicate for the Treatment of Hyperkalemia： a Systematic Review and MetaAnalysis[J]. Cardiovasc Drugs Ther， 2021，35(5)：10571066.
[23] Carvalho P， Veiga T， Lacerda H， et al. Safety and efficacy of new potassium binders on hyperkalemia management in patients with heart failure： a systematic review and metaanalysis of randomized controlled trials[J]. Clin Res Cardiol， 2023，112(7)：9911002.
[24] Fishbane S， Ford M， Fukagawa M， et al. A Phase 3b， Randomized， doubleblind， placebocontrolled study of sodium zirconium cyclosilicate for reducing the incidence of predialysis hyperkalemia[J]. J Am Soc Nephrol， 2019，30(9)：17231733.
[25] Ford M， Fishbane S， Spinowitz B， et al. Effectiveness of sodium zirconium cyclosilicate in hemodialysis patients with severe hyperkalemia[J]. Kidney Int Rep， 2021，6(12)：30743078.
[26] Yao L， Xing X， Li Y， et al. Effects of different potassiumlowering regimens on acute hyperkalemia in hemodialysis patients： a realworld， retrospective study[J]. J Transl Med， 2022，20(1)：333341.
[27] Ni Z， Lu R， Xu X， et al. DIALIZE China： A Phase Ⅲb， randomized， placebocontrolled study to reduce predialysis hyperkalemia with sodium zirconium cyclosilicate in Chinese patients[J]. Clin Ther， 2023，16(18)：110.
[28] 董生荣，景舒梦，苟伟康，等. 环硅酸锆钠治疗围透析期患者慢性高钾血症的有效性研究[J]. 中国卫生标准管理， 2023，14(2)：140143.
[29] 童成林，黄益麒.环硅酸锆钠治疗维持性血液透析患者高钾血症的疗效[J]. 江苏医药， 2021，47(09)：899902.
[30] 秦玉萍，路利娟，季帅燕.环硅酸锆钠散对维持性血液透析合并高钾血症患者短期降钾的疗效观察[J]. 南通大学学报(医学版)， 2022，42(3)：280282.
[31] Nasir K， Ahmad A.Treatment of hyperkalemia in patients with chronic kidney disease： a comparison of calcium polystyrene sulphonate and sodium polystyrene sulphonate[J]. J Ayub Med Coll Abbottabad， 2014，26(4)：455458.
[32] Nakayama Y， Ueda K， Yamagishi SI， et al. Compared effects of calcium and sodium polystyrene sulfonate on mineral and bone metabolism and volume overload in predialysis patients with hyperkalemia[J]. Clin Exp Nephrol， 2018，22(1)：3544.
[33] Nakamura T， Fujisaki T， Miyazono M， et al. Risks and benefits of sodium polystyrene sulfonate for hyperkalemia in patients on maintenance hemodialysis[J]. Drugs R D， 2018，18(3)：231235.
[34] Spinowitz B， McCafferty K， Fishbane S， et al. Dose effect analysis of sodium zirconium cyclosilicate in hemodialysis patients[J]. Hemodial Int， 2022，26(2)：274277.
[35] Hoy SM. Sodium Zirconium Cyclosilicate： A review in hyperkalaemia[J]. Drugs， 2018，78(15)：16051613.
[36] Levien TL， Baker DE. Sodium zirconium cyclosilicate[J]. Hosp Pharm， 2019，54(1)：1219.